First-line Ipilimumab + Paclitaxel/Carboplatin Improves PFS in NSCLC

Share this content:

(ChemotherapyAdvisor) – Phased ipilimumab plus paclitaxel and carboplatin improved immune-related progression-free survival (PFS) and PFS in patients with stage IIIB/IV non–small-cell lung cancer (NSCLC), supporting additional investigation in this population, a study in the Journal of Clinical Oncology online April 30 has found.

Previously, ipilimumab, an anticytotoxic T-cell lymphocyte-4 monoclonal antibody, has shown a survival benefit in melanoma, with adverse events (AEs) managed by protocol-defined guidelines, the investigators noted.

In this Phase 2 study, 204 patients with chemotherapy-naive NSCLC were randomly assigned 1:1:1 to receive paclitaxel 175mg/m2 and carboplatin (AUC, 6) with either placebo (control) or ipilimumab in one of two regimens: concurrent ipilimumab, which comprised 4 doses of ipilimumab plus paclitaxel and carboplatin followed by 2 doses of placebo plus paclitaxel and carboplatin, or phased ipilimumab, comprised of 2 doses of placebo plus paclitaxel and carboplatin followed by 4 doses of ipilimumab plus paclitaxel and carboplatin.

Treatment was administered intravenously every 3 weeks for ≤18 weeks as induction, with eligible patients continuing ipilimumab or placebo every 12 weeks as maintenance therapy.

The study met its primary end point of improved immune-response PFS for phased ipilimumab vs the control (HR, 0.72; P=0.05), but not for concurrent ipilimumab (HR 0.81; P =0.13). “Phased ipilimumab also improved PFS according to modified WHO criteria (HR 0.69; P=0.02),” the investigators wrote.

Phased ipilimumab was associated with a median immune-response PFS of 5.7 months; concurrent ipilimumab, 5.5 months; and control, 4.6 months. Median PFS was 5.1, 4.1, and 4.2 months, respectively. Immune-related best overall response rate was 32% in the phased ipilimumab group, 21% in the concurrent ipilimumab group, and 18% in the control group. Best overall response rate was 32%, 21% and 14%, respectively; median overall survival was 12.2, 9.7, and 8.3 months.

Overall rates of grade 3 and 4 immune-related adverse events were 15% for phased ipilimumab, 20% concurrent ipilimumab, and 6% for the control group. Two patients died from treatment-related toxicity, 1 each in the concurrent and control groups.

“…these results provide justification for additional investigation of ipilimumab in combination with chemotherapy in patients with NSCLC,” the investigators concluded.

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs